Forest Mealey, DO
Pulmonary Disease · Monterey, CANPI 1780664136
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Intuitive Surgical at 38.2% of the total. Reporting peaked in 2024 at $2,209 and has fallen 84.5% since, to $342 in 2025.
Across 41 payments — averaging $73.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Olympus Corporation Of The Americas$956
- Actelion Pharmaceuticals US, Inc.$211
- GSK$144
- United Therapeutics Corporation$134
- Sanofi-aventis U.S. LLC$89
- plus $329 from 10 others
Across 13 payments — averaging $17,311 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$214K
- Genentech, Inc.$11K
What the payments were for
- Travel & lodging$1,73057%
- Food & beverage$1,15138%
- Education$1234%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $1,150 |
| Olympus Corporation Of The Americas | 6 | $956 |
| Actelion Pharmaceuticals US, Inc. | 4 | $211 |
| GSK | 7 | $144 |
| United Therapeutics Corporation | 3 | $134 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| AstraZeneca | 2 | $58 |
| Insmed, Inc. | 3 | $55 |
| Pulmonx Corporation | 2 | $51 |
| Resmed Corp | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| Circassia Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,122
- Spiration Valve System$884
- UPTRAVI$134
- OPSUMIT$134
How this compares
$3,012 in reported general payments places this provider in the 60th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DuleraMometasone/Formoterol | 40 | $13,782 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $8,887 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $8,828 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $7,020 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $6,718 |
| BreynaBudesonide/Formoterol Fumarate | 37 | $5,869 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,577 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,119 |
| Fluticasone Propionate | 40 | $509 |
| Dexamethasone | 19 | $168 |
| Prednisone | 20 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckDulera | $14 | $13,78240 claims |
| GSKIncruse Ellipta, Breo Ellipta | $144 | $12,29535 claims |
| AstraZenecaSymbicort | $58 | $8,88730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Monterey
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.